← TrialMatch
HomeTrials

Effect of Dezocine Versus Nalbuphine Combined With Sufentanil on Postoperative Analgesia,

Background: Oral cancer radical surgery often requires free flap reconstruction. Postoperative pain is severe, and traditional opioids like sufentanil have side effects and may adversely affect tumor biology. Dezocine and nalbuphine are opioid agonist-antagonists with potentially better safety profiles. Their comparati

Condition(s)Oral Cancer, Postoperative Pain Management, Free Tissue Flaps, Mouth Neoplasms
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryBackground: Oral cancer radical surgery often requires free flap reconstruction. Postoperative pain is severe, and traditional opioids like sufentanil have side effects and may adversely affect tumor biology. Dezocine and nalbuphine are opioid agonist-antagonists with potentially better safety profiles. Their comparative effects on analgesia, complications, and flap survival in oral cancer surgery are unknown. Objective: To compare the efficacy of dezocine versus nalbuphine, both combined with sufentanil, for postoperative analgesia, and to evaluate their impact on postoperative complications and free flap survival/function in patients undergoing oral cancer radical surgery with flap reconstruction. Methods: This is a prospective, randomized, double-blind, controlled trial. Sixty eligible
Who can participateInclusion Criteria: 1. Diagnosed with oral malignant tumor. 2. Scheduled for oral cancer radical surgery with free flap reconstruction at Sun Yat-sen Memorial Hospital. 3. Age between 18 and 70 years. 4. Sign informed consent. Exclusion Criteria: 1. Use of analgesic medications within two weeks prior to surgery. 2. History of diabetes, arteriosclerosis, or peripheral vascular disease. 3. Use of hormones, chemotherapy, or immunosuppressants. 4. Severe cardiac, pulmonary, hematological, hepatic, or renal diseases. 5. Known allergy to the study drugs.
Ages18 Years to 70 Years
SexAll
Lead sponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
LocationsGuangzhou, Guangdong, China
Start date2025-06-01
NCT IDNCT07401641
Official listinghttps://clinicaltrials.gov/study/NCT07401641

🔍 Search all trials →